Immunophenotype and Prognosis in 510 Patients with Acute Myeloid Leukemia:A Single-Center Study

Objective:To investigate the immunophenotype characteristic of acute myeloid leukemia(AML) and reveal the correlation of prognosis with the immunophenotype. Method:Immunophenotyping was performed in AML patients by multicolor flow cytometry. Correlation of immunophenotype with prognosis was analyzed in AML patients excluding APL cases. Result:The myeloid lineage antigens positive expression(expressed by more than 20% of the blast cells) in 510 AML patients:CD13 was detected in 86.3% of evaluable cases,CD33 in 79.4%,HLA-DR in 66.9%,CD34 in 58.9%,CD117 in 55.4%,CD64 in 45.8%,CD7 in 29.2%,CD11b in 23.4%,CD56 in 18.9%,CD10 in 12.5%,CD15 in 11.6%,CD2 in 8.7%,CD19 in 8.5% and CD14 in 8.4%.CD34 and HLA-DR positive expression percentage were significantly lower in APL patients(P0.01).Patients with AML(excluding APL cases) blasts positive for CD10 and CD11b or high level expression(expressed by more than 50% of the blast cells) for CD13 and CD34 had significantly lower CR rates(P0.05,respectively) .The OS was significantly shorter in patients either with high level expression of CD13 or CD34 ,or expressing both CD13 and CD34 (P0.05,respectively). Conclusion:AML patients general expressed positive antigens with CD13,CD33,HLA-DR,CD34 and CD117.CD10,CD11b,CD13 and CD34 might be associated with the prognosis of the patients with AML(excluding APL).Immunophenotyping might be not only helpful for diagnosis but also of important significance for prognosis in AML patients.